Congestive heart failure: a half century perspective

[1]  J. Pogue,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. , 2000, The New England journal of medicine.

[2]  F. Alla,et al.  Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.

[3]  T. Lüscher,et al.  Endothelins and Endothelin Receptor Antagonists: Therapeutic Considerations for a Novel Class of Cardiovascular Drugs , 2000, Circulation.

[4]  M. Pfeffer,et al.  Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial , 2000, The Lancet.

[5]  T. LeJemtel,et al.  Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. , 2000, The New England journal of medicine.

[6]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[7]  K. T. Weber.  A whisper on the wind spawns a storm. , 2000, Cardiovascular research.

[8]  L. Leinwand,et al.  Myosin heavy chain isoform expression in the failing and nonfailing human heart. , 2000, Circulation research.

[9]  H. Sabbah,et al.  Apoptotic cell death in heart failure. , 2000, Cardiovascular research.

[10]  S. Vatner,et al.  Progressive loss of myocardial ATP due to a loss of total purines during the development of heart failure in dogs: a compensatory role for the parallel loss of creatine. , 1999, Circulation.

[11]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[12]  B. Bozkurt,et al.  Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. , 1999, Circulation.

[13]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[14]  R. Schwinger,et al.  Reduced Ca2+-Sensitivity of SERCA 2a in Failing Human Myocardium due to Reduced Serin-16 Phospholamban Phoshorylation , 1999 .

[15]  S. Lehnart,et al.  Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium. , 1999, Circulation.

[16]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[17]  Y. Sun,et al.  Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. , 1998, Circulation.

[18]  R. Collins,et al.  Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. , 1998, Circulation.

[19]  G. Radda,et al.  Mitral regurgitation: impaired systolic function, eccentric hypertrophy, and increased severity are linked to lower phosphocreatine/ATP ratios in humans. , 1998, Circulation.

[20]  E. Braunwald,et al.  Medical and cellular implications of stunning, hibernation, and preconditioning: an NHLBI workshop. , 1998, Circulation.

[21]  F. Clubb,et al.  Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.

[22]  R. Peshock,et al.  Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. , 1998, Circulation.

[23]  S. Neubauer,et al.  Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. , 1997, Circulation.

[24]  F. Lallemand,et al.  Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. , 1997, Circulation.

[25]  G. Mancia,et al.  Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. , 1997, Circulation.

[26]  G. Beller,et al.  Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability. , 1997, Circulation.

[27]  A. Struthers,et al.  Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. , 1997, Cardiovascular research.

[28]  M. Swindle,et al.  Premorbid determinants of left ventricular dysfunction in a novel model of gradually induced pressure overload in the adult canine. , 1997, Circulation.

[29]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[30]  G. Maurer,et al.  Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. , 1996, Journal of the American College of Cardiology.

[31]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .

[32]  G. Lamas,et al.  Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. , 1994, Circulation.

[33]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[34]  G. Lamas,et al.  Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. , 1988, The New England journal of medicine.

[35]  E. Braunwald,et al.  Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium". , 1986, Journal of the American College of Cardiology.

[36]  A. Mark,et al.  Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. , 1986, Circulation.

[37]  M. Pfeffer,et al.  Influence of Chronic Captopril Therapy on the Infarcted Left Ventricle of the Rat , 1985, Circulation research.

[38]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[39]  E. Braunwald,et al.  The Stunned Myocardium: Prolonged, Postischemic Ventricular Dysfunction , 1982, Circulation.

[40]  D C Harrison,et al.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.

[41]  M. Pfeffer,et al.  Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[42]  G. Whipple,et al.  Congestive heart failure following chronic tachycardia. , 1971, American heart journal.

[43]  E. Braunwald,et al.  Contractile State of Cardiac Muscle Obtained from Cats with Experimentally Produced Ventricular Hypertrophy and Heart Failure , 1967, Circulation research.

[44]  E. Braunwald,et al.  Myocardial High Energy Phosphate Stores in Cardiac Hypertrophy and Heart Failure , 1967, Circulation research.

[45]  E. Braunwald,et al.  Reduction of the Cardiac Response to Postganglionic Sympathetic Nerve Stimulation in Experimental Heart Failure , 1966 .

[46]  E. Sonnenblick,et al.  Norepinephrine Stores and Contractile Force of Papillary Muscle from the Failing Human Heart , 1966, Circulation.

[47]  E. Braunwald,et al.  CATECHOLAMINE EXCRETION AND CARDIAC STORES OF NOREPINEPHRINE IN CONGESTIVE HEART FAILURE. , 1965, The American journal of medicine.

[48]  E. Braunwald,et al.  MYOCARDIAL NOREPINEPHRINE CONCENTRATION IN MAN. EFFECTS OF RESERPINE AND OF CONGESTIVE HEART FAILURE. , 1963, The New England journal of medicine.

[49]  Branislav,et al.  Mechanical Circulatory Support : A Potential Mechanism for Cardiac Recovery in Failing Human Myocardium After α Decreased Expression of Tumor Necrosis Factor , 1999 .